Lista de obras - Asger Lund - Dominio Público Uruguay

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production

artículo científico publicado en 2017

Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects

artículo científico publicado en 2018

Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers

artículo científico publicado en 2018

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

artículo científico publicado en 2019

Emerging GLP-1 receptor agonists

artículo científico publicado en 2011

Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65:585-597

artículo científico publicado en 2016

Evidence of Extrapancreatic Glucagon Secretion in Man

article

Glucagon and type 2 diabetes: the return of the alpha cell.

artículo científico publicado en 2014

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals

article

Glucagon-like peptide 1 in health and disease

artículo científico publicado en 2018

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

artículo científico publicado en 2014

Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes

scientific article published on 16 July 2020

Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion

artículo científico publicado en 2016

Impaired regulation of the incretin effect in patients with type 2 diabetes

artículo científico publicado en 2011

Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes

artículo científico publicado en 2012

Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia

artículo científico publicado en 2015

Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

artículo científico publicado en 2018

Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake

artículo científico publicado en 2016

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

scientific article published on 16 January 2020

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes

artículo científico publicado en 2014

On the role of the gut in diabetic hyperglucagonaemia

artículo científico publicado en 2017

Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma

artículo científico publicado en 2016

Regulation of glucagon secretion by incretins

artículo científico publicado en 2011

Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

artículo científico publicado en 2019

The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial

artículo científico publicado en 2020

The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency

article

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

artículo científico publicado en 2011

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report

artículo científico publicado en 2014

Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.

artículo científico publicado en 2012

Lista de obras de Asger Lund

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production

Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects

Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Emerging GLP-1 receptor agonists

Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65:585-597

Evidence of Extrapancreatic Glucagon Secretion in Man

Glucagon and type 2 diabetes: the return of the alpha cell.

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals

Glucagon-like peptide 1 in health and disease

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes

Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion

Impaired regulation of the incretin effect in patients with type 2 diabetes

Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes

Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia

Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes

On the role of the gut in diabetic hyperglucagonaemia

Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma

Regulation of glucagon secretion by incretins

Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial

The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report

Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea.